ThaiPR.NET https://www.thaipr.net/location/paris-and-boston Press Release Distribution Center of Thailand Mon, 27 Apr 2026 14:40:01 +0700 hourly 1 https://wordpress.org/?v=6.1.1 <![CDATA[Servier’s Pivotal Phase 3 INDIGO Trial Investigating vorasidenib in IDH-Mutant Low-Grade Glioma Meets Primary Endpoint of Progression-Free Survival (PFS) and Key Secondary Endpoint of Time to Next Intervention (TTNI)]]> https://www.thaipr.net/en/health_en/3313935 Wed, 15 Mar 2023 08:41:18 +0700 health_en https://www.thaipr.net/en/health_en/3313935 Servier, a global pharmaceutical group, announced today that the Phase 3 INDIGO clinical trial investigating vorasidenib in monotherapy for patients with residual or recurrent IDH mutant low-grade glioma met its primary endpoint of progression free survival (PFS) and the key secondary endpoint of time to next intervention (TTNI). The results of the prespecified interim analysis […]

The post Servier’s Pivotal Phase 3 INDIGO Trial Investigating vorasidenib in IDH-Mutant Low-Grade Glioma Meets Primary Endpoint of Progression-Free Survival (PFS) and Key Secondary Endpoint of Time to Next Intervention (TTNI) appeared first on ThaiPR.NET.

]]> <![CDATA[Phase 3 Data Demonstrate TIBSOVO® (ivosidenib tablets) in Combination with Azacitidine Significantly Improves Event-Free Survival and Overall Survival in Patients with Previously Untreated IDH1-mutated Acute Myeloid Leukemia]]> https://www.thaipr.net/en/general_en/3132648 Mon, 13 Dec 2021 09:45:00 +0700 general_en https://www.thaipr.net/en/general_en/3132648 TIBSOVO in combination with azacitidine compared to placebo plus azacitidine also demonstrated significant improvements in complete remission rate, complete remission and complete remission with partial hematologic recovery rate and objective response rate Safety profile was favorable and consistent with previously published data Data from the Phase 3 AGILE trial of patients with previously untreated IDH1-mutated […]

The post Phase 3 Data Demonstrate TIBSOVO® (ivosidenib tablets) in Combination with Azacitidine Significantly Improves Event-Free Survival and Overall Survival in Patients with Previously Untreated IDH1-mutated Acute Myeloid Leukemia appeared first on ThaiPR.NET.

]]> <![CDATA[Servier Announces Positive Topline Data from the Global Phase 3 Study of TIBSOVO® (ivosidenib tablets) in Combination with Azacitidine in Patients with Previously Untreated IDH1-mutated Acute Myeloid Leukemia]]> https://www.thaipr.net/en/general_en/3081553 Mon, 02 Aug 2021 13:00:00 +0700 general_en https://www.thaipr.net/en/general_en/3081553 TIBSOVO is the first targeted therapy to show improved event-free survival and overall survival in combination with azacitidine compared to azacitidine monotherapy. Safety profile consistent with previously published data in patients with IDH1-mutated acute myeloid leukemia. The study recently halted further enrollment due to compelling efficacy data for TIBSOVO. Servier, a global pharmaceutical company, today […]

The post Servier Announces Positive Topline Data from the Global Phase 3 Study of TIBSOVO® (ivosidenib tablets) in Combination with Azacitidine in Patients with Previously Untreated IDH1-mutated Acute Myeloid Leukemia appeared first on ThaiPR.NET.

]]>